Faruqi & Faruqi, LLP is investigating claims against Anavex Life Sciences for allegedly misleading investors about internal controls and regulatory risks, including issues tied to former CEO Christopher Missling. Anavex's stock dropped sharply after withdrawing its EU drug application and firing Missling for cause. Investors who bought Anavex shares between Nov 26, 2025, and Aug 28, 2026, and suffered losses are encouraged to contact the law firm before the Nov 30, 2026 deadline to seek lead plaintiff status or join the class action. This lawsuit could lead to financial recovery for affected investors.
The Anavex Life Sciences shareholder notice is presented here with relevant health sector data for context. For readers following health stocks, 30 out of 100 priced US health-sector stocks on Pluang rose while 67 fell as of Oct 01, 2026 20:52 WIB. Among notable movers, ClearPoint Neuro Inc (CLPT) traded at USD 11.64 with a 1-day change of -4.67%, Heron Therapeutics Inc (HRTX) was priced at USD 0.33 with a +4.21% change, and American Well Corp (AMWL) stood at USD 13.01 with a -4.20% change.
Lamb Weston is set to report Q3 earnings with analysts forecasting an EPS of $0.59, down from $0.74 last year, and revenue around $1.65 billion, nearly flat compared to the prior year. The company’s "Focus to Win" strategy has generated over $100 mil...
Cal-Maine Foods reported a $58.6 million net loss and a 42% drop in net sales, driven by lower conventional egg prices. An analyst downgraded the stock to Hold with a $70 price target, reflecting a modest 2.85% upside from current levels. Despite cha...
PNC Financial Services Group received mixed analyst ratings on October 1, 2026. Evercore ISI maintained an Outperform rating but lowered its price target to $265 from $285, citing strong net interest income growth but caution on expenses and asset qu...
Accenture reported fiscal Q4 2026 earnings that exceeded analyst expectations with EPS of $3.29, up 46% year-over-year, and revenue of $18.68 billion, a 6% increase. The company also saw a 4% rise in new bookings to $22.17 billion, reflecting strong ...
Analysts have downgraded PepsiCo and lowered its price targets due to weak stock performance and sales challenges in its Frito-Lay North America segment. Despite efforts to improve products, sales remain sluggish, raising concerns about PepsiCo's ope...
